Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TT125-802 |
Synonyms | |
Therapy Description |
TT125-802 inhibits the bromodomain of CBP/p300, potentially leading to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 6268). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TT125-802 | TT125 802|TT125802 | CBP/p300 inhibitor 13 | TT125-802 inhibits the bromodomain of CBP/p300, potentially leading to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 6268). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06403436 | Phase I | TT125-802 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors (TT-CSP-001) | Recruiting | ESP | CHE | 0 |